Patents by Inventor Julien Taillemite

Julien Taillemite has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8987285
    Abstract: The present invention relates to a novel crystalline anhydrous form of [(5-chlorothiophene-2-ylsulfonylcarbamoyl)-(4-(6-fluoro-7-(methylamino)-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)phenyl)amide, potassium salt, and its use in the treatment or prevention of a condition or a disorder with platelet ADP receptor inhibition, in particular, P2Y12 inhibition, in animals, particularly humans. It also relates processes for making such a novel crystalline form. The present invention also relates to a solid, oral formulation of this novel crystalline form, its preparation and use thereof.
    Type: Grant
    Filed: December 5, 2011
    Date of Patent: March 24, 2015
    Assignee: Portola Pharmaceuticals, Inc.
    Inventors: Ulrich Meier, Nicole Bieri, Dieter Becker, Julien Taillemite, Marie-Pierre Filliot, Tanja Meister
  • Patent number: 8927028
    Abstract: A dosage form exhibiting delayed transit time through the GI tract. The dosage form comprises a plurality of buoyant particles, each comprising an inner drug-containing core, an intermediate layer surrounding said core and a release rate-controlling outer coating.
    Type: Grant
    Filed: December 15, 2005
    Date of Patent: January 6, 2015
    Assignee: Jagotec AG
    Inventors: Pascal Grenier, Julien Taillemite, Severine Serreau, Alain Nhamias
  • Publication number: 20130252979
    Abstract: The present invention relates to a novel crystalline anhydrous form of [(5-chlorothiophene-2-ylsulfonylcarbamoyl)-(4-(6-fluoro-7-(methylamino)-2,4-dioxo-1,2-dihydroquinazolin-3(4H)-yl)phenyl)amide, potassium salt, and its use in the treatment or prevention of a condition or a disorder with platelet ADP receptor inhibition, in particular, P2Y12 inhibition, in animals, particularly humans. It also relates processes for making such a novel crystalline form. The present invention also relates to a solid, oral for mulation of this novel crystalline form, its preparation and use thereof.
    Type: Application
    Filed: December 5, 2011
    Publication date: September 26, 2013
    Inventors: Ulrich Meier, Nicole Bieri, Dieter Becker, Julien Taillemite, Marie-Pierre Filliot, Tanja Meister
  • Publication number: 20100209480
    Abstract: The present invention relates to a pharmaceutical oral fixed dose combination comprising a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount of Valsartan, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical oral fixed dose combination shows an in vitro dissolution of component a) of 80% or less after 10 minutes and 98% or less after 20 minutes, and a dissolution profile of component b) of 25% or more after 30 minutes, and 40% or more after 60 minutes at pH 4.5.
    Type: Application
    Filed: September 24, 2008
    Publication date: August 19, 2010
    Inventors: Ralf Altenburger, Maggy B. Saunier, Nicole Bargenda, Michael A. Bock, Sabine Adler, Bruno Buss, Catherine Curdy, Indrajit Ghosh, Stefan Hirsch, Patrice F. Keller, Charu Kochhar, Shoufeng Li, Nicoletta Loggia, Amol S. Matharu, Julien Taillemite, Wei-Qin Tong, Sudha Vippagunta, Hong Wen, Marie-Christine Wolf, Jay P. Lakshman, James Kowalski
  • Publication number: 20080317841
    Abstract: A dosage form exhibiting delayed transit time through the GI tract. The dosage form comprises a plurality of buoyant particles, each comprising an inner drug-containing core, an intermediate layer surrounding said core and a release rate-controlling outer coating.
    Type: Application
    Filed: December 15, 2005
    Publication date: December 25, 2008
    Inventors: Pascal Grenier, Julien Taillemite, Severine Serreau, Alain Nhamias